Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds

El-Masry,Omar  S.; Brown,Barry  L.; Dobson,Pauline  R.M.

doi:10.3892/ol.2011.458

Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds

Authors:
- Omar S. El-Masry
- Barry L. Brown
- Pauline R.M. Dobson
View Affiliations

Affiliations: Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield S10 2TN, UK
Published online on: October 21, 2011 https://doi.org/10.3892/ol.2011.458
Pages: 224-228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer remains a therapeutic challenge, and this has intensified the search for new drug targets. The AMP-activated protein kinase (AMPK) signalling pathway is emerging as having potential for intervention. We assessed the possible different effects of AMPK action on breast cancer cells by studying their impact on proliferation, apoptosis and the mitochondrial membrane potential in three breast cancer cell lines (MCF-7, MDA-MB-231 and T47D) differing in their p53 and estrogen receptor (ER) status. Activation of AMPK by 5-aminoimidazole carboxamide ribonucleotide (AICAR) and phenformin elicited clear anti-proliferative effects in all breast cancer cell lines, but with differences in sensitivity. However, the anti-proliferative effects were accompanied by varying responses between the different cells, with a marked cell cycle arrest effect in T47D cells and an apoptotic effect in MCF-7 and MDA-MB-231 cells. The mitochondrial apoptotic pathway was potentially involved in all cell lines. These results suggest that AMPK potentially serves as a therapeutic target in breast cancer, but one which may be dependent on the genetic background of the cancer cells.

View Figures

View References

1	Evans DG and Howell A: Breast cancer risk-assessment models. Breast Cancer Res. 9:2132007. View Article : Google Scholar : PubMed/NCBI
2	Lorincz AM and Sukumar S: Molecular links between obesity and breast cancer. Endocr Relat Cancer. 13:279–292. 2006. View Article : Google Scholar : PubMed/NCBI
3	Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I and Tisdale MJ: Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res. 58:2353–2358. 1998.PubMed/NCBI
4	Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M and Makela TP: The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta. 1775:63–75. 2007.PubMed/NCBI
5	Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG and Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23:833–843. 2004. View Article : Google Scholar : PubMed/NCBI
6	Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R and Bertrand L: AMPK: Lessons from transgenic and knockout animals. Front Biosci. 14:19–44. 2009. View Article : Google Scholar : PubMed/NCBI
7	Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805. 2004. View Article : Google Scholar : PubMed/NCBI
8	Caraci F, Chisari M, Frasca G, Chiechio S, Salomone S, Pinto A, Sortino MA and Bianchi A: Effects of phenformin on the proliferation of human tumor cell lines. Life Sci. 74:643–650. 2003. View Article : Google Scholar : PubMed/NCBI
9	Luo Z, Saha AK, Xiang X and Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 26:69–76. 2005. View Article : Google Scholar : PubMed/NCBI
10	Xiang X, Saha AK, Wen R, Ruderman NB and Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 321:161–167. 2004. View Article : Google Scholar : PubMed/NCBI
11	Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 280:39582–39593. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yang L, Cao Z, Yan H and Wood WC: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 63:6815–6824. 2003.PubMed/NCBI
13	Butler H and Korbonits M: Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 161:655–662. 2009. View Article : Google Scholar : PubMed/NCBI
14	Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I and Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer. 6:462007. View Article : Google Scholar : PubMed/NCBI
15	Mukherjee P, Mulrooney TJ, Marsh J, Blair D, Chiles TC and Seyfried TN: Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Mol Cancer. 7:372008. View Article : Google Scholar : PubMed/NCBI
16	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI